Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On Terminating, Ending, and Not Ending.

The Psychoanalytic quarterly·2025
Same author

Psychic Song and Dance: Dissociation and Duets in the Analysis of Trauma.

The Psychoanalytic quarterly·2022
Same author

Dissociation: Dissemblance or Dis-Assembly? Commentary on Diamond.

Journal of the American Psychoanalytic Association·2020
Same author

Becoming related: the education of a psychoanalyst.

The Psychoanalytic quarterly·2014
Same author

The analyst's excitement in the analysis of perversion.

The International journal of psycho-analysis·2006
Same author

The analyst's theory: a third source of countertransference.

The International journal of psycho-analysis·2004

Related Experiment Video

Updated: Jun 30, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

The analyst's attitude toward pharmacotherapy.

Stephen D Purcell1

  • 1San Francisco Center for Psychoanalysis, Psychoanalytic Institute of Northern California, San Francisco, CA 94115, USA. purcellsd@comcast.net

Journal of the American Psychoanalytic Association
|September 20, 2008
PubMed
Summary
This summary is machine-generated.

The integration of medication into psychoanalysis requires careful consideration of potential adverse psychological effects. An analyst's attitude towards pharmacotherapy can influence transference-countertransference dynamics and lead to resistances.

Related Experiment Videos

Last Updated: Jun 30, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

  • Psychiatry
  • Psychoanalysis
  • Psychology

Background:

  • The increasing use of pharmacotherapy in psychoanalytic treatment necessitates a thorough examination of its potential complications.
  • While diagnostic criteria guide treatment, the decision to combine medication with psychoanalysis involves complex transference-countertransference dynamics.

Observation:

  • The psychoanalyst's stance on pharmacotherapy can be a significant factor in defensive and gratifying enactments.
  • These enactments, or resistances, can disrupt the psychoanalytic process.

Findings:

  • Clinical examples demonstrate how narcissistic and perverse resistances can be exacerbated by the analyst's attitudes toward medication.
  • Tacit communication of the analyst's views on pharmacotherapy influences decisions regarding combined treatment.

Implications:

  • Further research is needed to understand the intricate interplay between pharmacotherapy and psychoanalytic processes.
  • Clinicians must be mindful of how their attitudes toward medication may inadvertently foster resistances in psychoanalytic patients.